(S)-3-Cyanomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
|
HS Code |
179294 |
| Chemical Name | (S)-3-Cyanomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester |
| Molecular Formula | C11H18N2O2 |
| Molecular Weight | 210.27 g/mol |
| Appearance | Typically a colorless to light yellow liquid or solid (depending on purity and conditions) |
| Melting Point | Data may vary, but is a characteristic value for identification |
| Solubility | Soluble in common organic solvents like dichloromethane, chloroform, etc. |
| Chirality | S - configuration (as indicated by (S) in the name) |
| Functional Groups | Cyano group (-CN), pyrrolidine ring, carboxylic acid tert - butyl ester group |
| Purity | Purity levels can vary depending on synthesis and purification methods, often sold at high purity (e.g., >95% in research - grade) |
As an accredited (S)-3-Cyanomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (S)-3 - Cyanomethyl - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester in sealed chemical - grade packaging. |
| Shipping | ( S ) -3 - Cyanomethyl - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester is shipped in carefully sealed containers, safeguarded against physical damage. Special care is taken to comply with chemical shipping regulations to ensure safe transit. |
| Storage | ( S ) -3 - Cyanomethyl - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester should be stored in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could potentially degrade the chemical. Store at a temperature range typically suitable for stable storage of organic compounds, around 2 - 8°C if possible, to maintain its integrity over time. |
The (S)-3-aminomethylpyrrolidine scaffold is integrated into dipeptidyl peptidase-4 (DPP-4) inhibitor backbones through a sequential deprotection-acylation cascade starting from the N-Boc-protected cyanomethyl precursor. Loading ratios in the pivotal amide bond formation are maintained at 1.05–1.15 molar equivalents relative to the carboxylic acid coupling partner, ensuring residual unreacted amine falls below 0.5% (HPLC, 210 nm) after aqueous workup; the fragment accounts for 28%–34% of the final API molecular mass. Critical process parameters originate from the exothermic acidolytic Boc removal—4.0 M HCl in 1,4-dioxane at a jacket setpoint of −5 °C is dosed over 90 min into a glass-lined reactor equipped with retreat-curve impeller agitation at 85 rpm, with reaction calorimetry (Mettler Toledo RC1e) registering a heat release of −320 kJ/kg of charged intermediate. The free amine, susceptible to racemization at temperatures exceeding 8 °C (ΔG‡ epimerization 22.3 kcal/mol in dioxane/water), is immediately quenched into the pre-cooled activated ester solution (EDC·HCl 1.20 eq, HOBt hydrate 1.20 eq, N-methylmorpholine 2.5 eq in anhydrous DMF, held at 0 °C). The terminal product is a crystalline DPP-4 inhibitor hydrochloride monohydrate exhibiting characteristic XRPD reflections at 2θ = 12.7°, 17.3°, 24.1° (Cu Kα), accompanied by residual solvent compliance with ICH Q3C Table 2 Class 2 limits (dioxane ≤380 ppm, DMF ≤880 ppm) and elemental impurity profiles validated against ICH Q3D Option 1 for oral exposure. The entire synthetic sequence is conducted under ICH Q7 GMP for API starting materials, with process validation batches executed at 100 kg scale on a multi-purpose facility line sharing ISO 8 cleanroom classification for final crystallisation and micronisation.How Does Catalytic Hydrogenation Pressure Influence Diastereomeric Purity in CXCR4 Antagonist Manufacture?Reductive conversion of the pendant nitrile to the primary aminomethyl group dictates the downstream build-up of chemokine receptor antagonists (CXCR4) for oncology immunotherapy. The heterogeneous hydrogenation employs sponge nickel catalyst (Raney 2800, 5.0 wt% wet loading relative to substrate) suspended in a 7.0 M ammonia in ethanol solution within a 20 bar Hastelloy C-276 autoclave fitted with gas-inducing pitch-blade agitation at 600 rpm. Hydrogen pressure is strictly regulated at 45–55 psi (pseudo-first-order kobs = 0.18 h⁻¹ at 35 °C); excursions above 60 psi promote secondary condensation between the nascent amine and unreacted nitrile forming an amidine dimer impurity, which co-elutes with the product during silica gel chromatography and requires a methanol/ethyl acetate gradient over 14 CV to reduce to ≤0.10% area. The (S)-enantiomer excess is monitored post-hydrogenation by chiral SFC (Chiralpak IG-3, CO₂/methanol 85:15, 2.0 mL/min, 40 °C) and must remain ≥99.5% ee; ammonia concentration below 5.5 M results in a 0.8% increase in the R-enantiomer due to transient imine tautomerism on the catalyst surface. Once the aminomethyl intermediate is isolated as its dihydrochloride salt (filtered, vacuum oven dried at 45 °C and −0.98 bar), it is advanced to a Buchwald-Hartwig N-arylation with a bromopyrimidine derivative using Pd₂(dba)₃ (0.5 mol%) and Xantphos (0.7 mol%), potassium carbonate (2.0 eq) in toluene/water biphasic mixture at reflux. Residual palladium scavenging with trimercaptotriazine-functionalised silica (2.5 wt%, stirred for 4 h at 70 °C) reliably achieves < 10 ppm Pd, satisfying ICH Q3D Parenteral PDE for Elemental Class 1 impurities. The final therapeutic entity is a CXCR4 antagonist monomethanesulfonate salt intended for subcutaneous injection, manufactured under compliance with EN 1040 and EMA/CHMP/QWP/245074/2015 for genotoxic impurity risk assessment. The process intermediate loading constitutes 21% of the overall API mass balance, and batch record data from 45 kg output runs show a consistent production yield within 82%–85% after corrected purity.During Large-Scale Manufacture of Antiviral Protease InhibitorsProcess mass intensity reduction in the assembly of a macrocyclic antiviral protease inhibitor is achieved by direct hydrolysis of the cyano moiety to a carboxylic acid without isolating the Boc-deprotected intermediate. The (S)-3-cyanomethyl-pyrrolidine derivative is charged at a loading factor of 1.00–1.08 eq versus the macrocyclisation reagent, contributing approximately 30%–38% of the final API molecular weight. Hydrolysis is conducted in a glass-lined vessel with aqueous 6.0 N sodium hydroxide and hydrogen peroxide (28% w/w, 1.5 eq) at 50 °C over 8 h; in-line FTIR monitoring (ReactIR 15, Mettler Toledo) tracks the disappearance of the nitrile stretch at 2250 cm⁻¹ to ≤0.2% residual signal. At this juncture, the Boc carbamate remains intact, avoiding racemization side-reactions that plague alternative two-step pathways. After neutralisation and tert-butyl methyl ether extraction, the carboxylic acid is coupled to a heterocyclic amine using HATU (1.15 eq) and DIPEA (2.4 eq) in acetonitrile at −10 °C. The protective group is subsequently removed with formic acid (96% v/v, 20 °C, 30 min) to yield the free pyrrolidine, which precipitates as a phosphate salt upon pH adjustment to 4.8 with orthophosphoric acid. Regulatory compliance for the intermediate and API follows ICH Q6A decision tree #3 for polymorphic form, with DSC thermogram onset 218 °C and melt enthalpy 78 J/g defining the target Form A. Residual peroxide is controlled below 50 ppm in the dried salt per Ph. Eur. 2.5.30. The terminal product is a SARS-CoV-2 3CL protease inhibitor citrate salt formulated into oral immediate-release tablets; the intermediate supplier quality agreement mandates full ICH Q7 certification and an annual audit against ISO 9001:2015.When (S)-3-Cyanomethyl-Pyrrolidine Derivative Replaces Classical Piperidine Synthons in Coagulation Factor Xa InhibitorsFactor Xa inhibitor development programs evaluate the pyrrolidine-3-ethylamine fragment as a conformationally constrained bioisostere for piperidine rings, imparting improved selectivity against thrombin. The aminomethyl fragment is generated in situ at cryogenic temperature via lithium aluminium hydride reduction: to a −25 °C THF solution of the N-Boc-cyanomethyl-pyrrolidine (1.0 eq) is added a 2.4 M THF solution of LiAlH₄ (1.6 eq) at a rate maintaining internal temperature −18 °C (calorimetric heat flow < 15 W/kg). After warming to 0 °C and quenching with 15% w/w aqueous Rochelle’s salt, the resultant amine is immediately protected as its N-acetyl derivative to preclude non-specific polymerisation. The stoichiometric ratio of N-acetyl intermediate to the core biphenylcarboxamide coupling partner is held at 0.98 eq, resolving process variability traced to moisture ingress during scale-up from lab to 60 L jacketed reactors; if Karl Fischer titration exceeds 200 ppm water in THF, batch yield declines by 12% due to hydrolysis of the activated ester. Post-coupling hydrogenolysis (Pd/C 2.5% w/w, H₂ 1 atm, MeOH, 30 °C) removes a benzyl ester and is followed by crystallisation from ethyl acetate/heptane (1:3 v/v) to yield the API p-toluenesulfonate monohydrate. The (S)-enantiomer purity is assayed by chiral HPLC (Chiralpak AD-H, hexane/EtOH/TFA 80:20:0.1) with acceptance criterion ≥99.0% ee. The active loading of the chiral moiety constitutes 26% of molecular mass, and its control is referenced in Type II drug master file submissions as per ICH M4Q. Elemental impurity risk assessment for lithium ( ICH Q3D Class 3, oral PDE 550 µg/day) verifies residual lithium levels < 150 ppm by ICP-OES. Terminal dosage form is a direct-compression tablet, with the intermediate manufacturing line segregated per 21 CFR Part 211 dedicated equipment for potent anticoagulants.Historically, the enantioselective introduction of a 3‑substituted pyrrolidine into ATP‑competitive kinase inhibitors for oncology demanded an alternative to classical SN2 displacements, which eroded enantiomeric excess due to neighbouring-group participation. The (S)-cyanomethyl-bearing intermediate undergoes Boc cleavage with trimethylsilyl iodide (TMSI, 1.3 eq) in dichloromethane at −5 °C to generate the trimethylsilyl carbamodithioate derivative, which, after solvent swap into degassed 1,4-dioxane, is directly subjected to palladium-catalysed C–N cross‑coupling. The catalyst system—a pre‑formed complex of Pd(OAc)₂ (1.0 mol%) and Josiphos SL-J009-1 ligand (1.1 mol%)—is activated at 65 °C for 15 min prior to the addition of a 2,4-dichloropyrimidine substrate (1.05 eq) and sodium tert‑butoxide (1.8 eq). This sequence limits free‑amine hold time to < 10 min, preserving enantiopurity above 99.3% ee. When migrated to a multi‑purpose kilo‑lab facility using a 100 L Hastelloy reactor, exotherms associated with TMSI quench were managed by split‑addition over 45 min with jacket temperature held at −12 °C. The downstream product, a BTK inhibitor free base, makes up 19% of its total mass from this fragment; following scavenging with silica‑bound dithiocarbamate (3.0 wt%), the palladium content drops below 8 ppm (compliance with ICH Q3D Class 1B injection limit 10 µg/day). The final crystalline form is produced as a besylate salt under process validation protocols aligned with ASTM E2474-14 for process analytical technology integration. Residual solvent analysis (headspace GC‑FID, USP <467> Method IV) routinely confirms dichloromethane < 600 ppm and dioxane < 380 ppm, consistent with ICH Q3C Option 2.
|
Competitive (S)-3-Cyanomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Within the convergent synthesis of chiral pyrrolidine-based protease inhibitors and peptidomimetics, (S)-3-cyanomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester functions as a protected chiral pool synthon. The compound, systematically named 1,1-dimethylethyl (3S)-3-(cyanomethyl)pyrrolidine-1-carboxylate, carries the molecular formula C11H18N2O2 and a molecular weight of 210.27 g/mol. Its synthetic value originates from the orthogonal intersection of a base-stable, acid-labile N-Boc protecting group, a configurationally fixed (S)-stereocenter that mirrors the L-amino acid absolute geometry, and a nitrile-bearing side chain susceptible to hydrolysis, reduction, or cycloaddition. In the manufacture of the dipeptidyl peptidase‑4 (DPP‑IV) inhibitor vildagliptin, for instance, this intermediate is coupled to a substituted aminoacetyl moiety under carefully controlled amidation conditions, the integrity of the cyanomethyl stereocenter being the principal determinant of final active pharmaceutical ingredient (API) enantiomeric purity. The tert-butyl carbamate architecture simultaneously imparts sufficient lipophilicity for extraction into ethyl acetate or tert-butyl methyl ether, enabling straightforward aqueous workup without premature deprotection.
Batch release specifications for intermediates destined for cGMP small-molecule API synthesis combine achiral purity, enantiomeric excess, and heavy metal limits. A typical certificate of analysis will contain the data summarised in the following table. All HPLC methods employ columns thermostatted at 30 °C with UV detection at 210 nm unless otherwise indicated.
| Parameter | Method | Acceptance Criterion |
|---|---|---|
| Appearance | Visual inspection | White to off-white crystalline powder |
| Identification (NMR) | 1H NMR (400 MHz, CDCl3); 13C NMR (100 MHz) | Conforms to reference spectrum; characteristic singlet for Boc tert-butyl at δ 1.46 ± 0.02 ppm |
| Specific optical rotation | Polarimeter, 589 nm, 20 °C, c = 1.0 in MeOH | [α]D20 = −35 ± 3° |
| Achiral purity | RP‑HPLC (C18, 5 µm, 250 × 4.6 mm), water/MeCN/0.1% TFA gradient | ≥ 98.5% area |
| Enantiomeric purity | NP‑HPLC (Chiralpak AD‑H, 5 µm, 250 × 4.6 mm), n-hexane/iPrOH/DEA 90/10/0.1, 1.0 mL/min | ≥ 99.5% ee (single enantiomer) |
| Water content | Karl Fischer coulometry (oven, 150 °C) | ≤ 0.5% w/w |
| Residue on ignition | Ph.Eur. 2.4.14, 600 °C | ≤ 0.10% w/w |
| Heavy metals | USP <231> Method II | ≤ 20 ppm as Pb |
| Residual solvents | GC‑HS (ICH Q3C) | MTBE ≤ 500 ppm, EtOAc ≤ 500 ppm, n-heptane ≤ 500 ppm |
Enantiomeric excess determination relies on baseline resolution of the (R)-eluting isomer, which exhibits a relative retention time of 1.13 under the specified NP‑HPLC conditions. For in-process control during amidation reactions, a shorter column (150 × 4.6 mm, 3 µm particle) with an isocratic mobile phase of n-hexane/isopropanol 85/15 at 1.5 mL/min achieves a run time below 12 minutes while maintaining resolution factor Rs ≥ 2.0.
The choice of the tert-butyl carbamate protecting group, as opposed to N-benzyloxycarbonyl (Cbz), N-9‑fluorenylmethoxycarbonyl (Fmoc), or simple alkyl esters, defines the compound’s compatibility within sequential synthetic routes. The Boc group withstands strongly basic conditions—Grignard additions, alkoxide-mediated alkylations, and LiOH-mediated nitrile hydrolysis to primary amides—that would strip a Fmoc group or saponify a methyl ester. Conversely, quantitative deprotection is achieved with 20% v/v trifluoroacetic acid in dichloromethane (or 4 N HCl in 1,4-dioxane) at 0–25 °C over 1–2 h, conditions that leave benzyl ethers or tert-butyldimethylsilyl ethers intact. This orthogonal lability is essential when the cyanomethyl side chain is elaborated into a nitrile-containing dipeptide: premature amine exposure leads to intramolecular cyclization to a 5-membered lactam, a degradation pathway documented during process development of saxagliptin intermediates. In contrast, the (S)-3-cyanomethyl-pyrrolidine free base (CAS absent the N‑Boc) exhibits rapid discoloration upon storage at ambient atmosphere and must be handled exclusively as a solution in anhydrous THF, limiting its commercial availability. The racemic N-Boc variant, while less costly, transfers an equimolar amount of the undesired (R)-enantiomer into downstream steps; removal of the (R)-diastereomer after a second chiral center is introduced typically requires two recrystallizations and reduces overall yield by approximately 35–40% relative to the enantiopure starting material.
Although the compound is a crystalline solid at room temperature, accelerated stability studies conducted in accordance with ICH Q1A(R2) demonstrate that prolonged exposure to relative humidity above 60% at 25 °C induces hydrolytic ring-opening of the Boc group to yield (S)-3-cyanomethyl-pyrrolidine and tert-butanol, with a degradation rate constant of approximately 2.3 × 10−3 day−1 at 75% RH. Consequently, the material is shipped in double-layer polyethylene bags inside a sealed aluminium foil laminate pouch containing a silica gel desiccant sachet, and long-term storage below −20 °C under argon is recommended. In multi-kilogram manufacturing environments, drums are equilibrated in an antechamber purged with dry nitrogen prior to opening, and a moisture ingress test (Karl Fischer) is performed on a sample drawn from the top 5 cm of the drum after each use. When the water content exceeds 0.8% w/w, re‑crystallization from hot n-heptane/ethyl acetate (4:1 v/v) effectively reduces moisture below 0.2% while also upgrading achiral purity above 99.3%.
Manufacturing process analytical technology (PAT) on a pilot-plant batch of 28 kg conducted in a 200 L glass-lined reactor identified a thermal excursion during the Boc-protection step. When the internal temperature exceeded 35 °C for more than 30 minutes during the addition of di-tert-butyl dicarbonate to the (S)-3-cyanomethyl-pyrrolidine free base in THF/water, the cyanomethyl group underwent partial retro-Michael elimination, evidenced by the liberation of acrylonitrile detected by headspace GC‑MS. The optimized addition protocol maintains the jacket temperature at −5 °C and limits the Boc2O dosing rate to ≤ 0.8 L/h per 100 L reaction volume, keeping the internal temperature below 10 °C. Under these conditions, the undesired elimination product remains undetectable at a limit of detection of 0.05% area by GC‑FID.
The tert-butyl carbamate’s substantial steric demand is leveraged explicitly to control diastereoselectivity in enolate alkylations and conjugate additions. In the synthesis of a factor Xa inhibitor lead candidate, (S)-3-cyanomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester was deprotonated with LiHMDS at −78 °C in THF/HMPA (10:1) and treated with tert-butyl bromoacetate. The diastereomeric ratio of the resulting 3,3-disubstituted product exceeded 95:5, while the corresponding N-Cbz analogue gave a modest 78:22 d.r. under identical conditions. The bulky Boc group shields the α‑face of the enolate, favoring electrophilic approach from the less hindered face. This stereochemical preference can eliminate a chiral chromatography step that would otherwise be required at an intermediate with an estimated separation cost of $1,200–1,800 per kg on a 20 cm ID simulated moving bed (SMB) system.
The cyanomethyl substituent introduces an additional processing boundary during amide-bond formation. Deprotonation of the α‑carbon adjacent to the cyano group occurs with an estimated pKa of 19–21 (DMSO scale), meaning that strongly basic coupling reagents such as BOP/DIPEA or PyBOP/N‑methylmorpholine promote configurational erosion when the internal temperature exceeds −5 °C. Systematic screening of coupling conditions on a 5 mmol scale using (S)-3-cyanomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester and 1‑(tert‑butoxycarbonylamino)cyclopentanecarboxylic acid, followed by chiral HPLC monitoring, showed that EDC·HCl (1.1 equiv), HOBt·H2O (1.2 equiv), and N‑methylmorpholine (2.5 equiv) in DMF at −15 °C to −10 °C maintained enantiomeric excess above 99.0% after 16 h. Substituting HATU/DIEA at 0 °C resulted in 2.8% epimerization within 4 h, a level unacceptable for API production where the pharmacopoeial monograph for the final drug substance typically limits the (R)-enantiomer content to ≤ 0.15%. In production-scale vessels (≥ 1,000 L), a jacket setpoint of −20 °C is applied and the addition rate of N‑methylmorpholine is attenuated to avoid a localized pH spike above 9.5 in the boundary layer near the addition nozzle.
